Title
Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics
Author
Koudstaal, W.
Hartgroves, L.
Havenga, M.
Legastelois, I.
Ophorst, C.
Siewerts, M.
Zuijdgeest, D.
Vogels, R.
Custers, J.
de Boer-Luijtze, E.
de Leeuw, O.
Cornelissen, L.
Goudsmit, J.
Barclay, W.
TNO Kwaliteit van Leven
Publication year
2009
Abstract
Reverse genetics, the generation of influenza viruses from cDNA, presents a rapid method for creating vaccine strains. The technique necessitates the use of cultured cells. Due to technical and regulatory requirements, the choice of cell lines for production of human influenza vaccines is limited. PER.C6® cells, among the most extensively characterized and documented cells, support growth of all influenza viruses tested to date, and can be grown to high densities in large bioreactors in the absence of serum or micro carriers. Here, the suitability of these cells for the generation of influenza viruses by reverse genetics was investigated. A range of viruses reflective of vaccine strains was rescued exclusively using PER.C6 cells by various transfection methods, including an animal component-free procedure. Furthermore, a whole inactivated vaccine carrying the HA and NA segments of A/HK/156/97 (H5N1) that was both rescued from and propagated on PER.C6 cells, conferred protection in a mouse model. Thus PER.C6 cells provide an attractive platform for generation of influenza vaccine strains via reverse genetics. © 2009 Elsevier Ltd. All rights reserved.
Subject
Biology
Biomedical Research
Animals
Antibodies, Viral
Cell Culture Techniques
Cell Line
Female
Hemagglutination Inhibition Tests
Humans
Influenza A Virus, H1N1 Subtype
Influenza A Virus, H3N2 Subtype
Influenza A Virus, H5N1 Subtype
Influenza Vaccines
Influenza, Human
Mice
Mice, Inbred BALB C
Plaque Assay
Reassortant Viruses
Severity of Illness Index
Survival Analysis
Transfection
To reference this document use:
http://resolver.tudelft.nl/uuid:b96d387c-7c45-4536-b0a2-6fe4a0c33ae1
DOI
https://doi.org/10.1016/j.vaccine.2009.02.033
TNO identifier
285080
Source
Vaccine, 27 (19), 2588-2593
Document type
article